



Paris, 22 May 2014, 7:00 pm

**Despite results considered as promising, AB Science receives a negative opinion from the CHMP on appeal for conditional authorization of Masitinib in pancreatic cancer.**

**AB Science intends to file for full approval in this indication with data from confirmatory phase 3 study.**

**AB Science SA** (NYSE Euronext – FR0010557264 – AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicine Agency (EMA) has adopted a negative opinion on the conditional marketing authorization for Masiviera (Masitinib mesylate) for the first line treatment of non resectable locally advanced or metastatic pancreatic cancer. This decision is on the appeal filed by AB Science following a previous negative opinion adopted by the CHMP in January 2014.

The Rapporteurs considered that the evidences presented in the pain and in the genetic subgroups were very promising, but that the benefit was not sufficiently demonstrated since the data were derived from subgroup analysis. The safety profile of masitinib did not raise major issues in consideration of other more toxic alternatives used in pancreatic cancer. In addition, although a couple of control actions requested by the CHMP still needed to be implemented at the end of the procedure, most outstanding quality issues were resolved. However, in the absence of demonstrated benefit, CHMP considered that the benefits of masitinib did not outweigh its risks at this stage of the development of masitinib. The phase 3 confirmatory study will be necessary to clearly demonstrate the benefit of masitinib in the target subgroups, which account for approximately 60% of the pancreatic cancer patients.

For clarity and transparency, the oral presentation delivered to CHMP by AB Science and detailing the case can be viewed on AB Science website, in the “News” section.

This decision does not affect the perspective to obtain marketing authorization of masitinib in this indication. AB Science intends to file for marketing authorization with data from the phase 3 confirmatory study to be initiated in the first line treatment of non resectable locally advanced or metastatic pancreatic cancer.

#### **About masitinib**

Masitinib received orphan drug status from EMA and FDA in the treatment of GIST.

Masitinib is a new orally administered tyrosine kinase inhibitor that targets mast cells, important cells for immunity, as well as a limited number of kinases that play key roles in various cancers. Owing to its novel mechanism of action, masitinib can be developed in a large number of conditions in oncology, in inflammatory diseases, and in certain diseases of the central nervous system. Through its activity of inhibiting certain kinases that are essential in some oncogenic processes, masitinib may have an effect on tumor regression, alone or in combination with chemotherapy. Through its activity on the mast cell and certain kinases essential to the activation of the inflammatory cells and fibrosing tissue remodeling, masitinib can have an effect on the symptoms associated with some inflammatory and central nervous system diseases.

#### **About AB Science**

Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a new class of targeted molecules whose action is to modify

signaling pathways within cells. Through these PKIs, the Company targets diseases with high unmet medical needs (cancer, inflammatory diseases, and central nervous system diseases), in both human and veterinary medicines. AB Science has developed a proprietary portfolio of molecules and the Company's lead compound, masitinib, has already been registered for veterinary medicine in Europe and in the USA, and is pursuing thirteen phase 3 studies in human medicine in first-line and second-line GIST, metastatic melanoma expressing JM mutation of c-Kit, multiple myeloma, metastatic colorectal cancer, metastatic prostate cancer, pancreatic cancer, mastocytosis, severe persistent asthma, rheumatoid arthritis, Alzheimer's disease, progressive forms of multiple sclerosis, and Amyotrophic Lateral Sclerosis. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).

Further information is available on AB Science website: [www.ab-science.com](http://www.ab-science.com).

*This document contains prospective information. No guarantee can be given as for the realization of these forecasts, which are subject to those risks described in documents deposited by the Company to the Authority of the financial markets, including trends of the economic conjuncture, the financial markets and the markets on which AB Science is present.*

\* \* \*

*AB Science – Financial Communication & Media Relations  
investors@ab-science.com*